Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 15/20 | 0.58 |
| ▸ | SLC5A1 | P13866 | 15/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.34 |
| ▸ | WNT3A | P56704 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13677629 | 0.88 | SLC5A2 (0.57) | SLC5A2SLC5A1CYP19A1CTNNB1WNT3A | |
| SCHEMBL13554620 | 0.88 | SLC5A2 (0.55) | SLC5A2SLC5A1CYP19A1CTNNB1WNT3A | |
| SCHEMBL1682184 | 0.78 | SLC5A1 (0.63) | SLC5A2SLC5A1CYP19A1CTNNB1WNT3A | |
| SCHEMBL3411626 | 0.76 | SLC5A2 (0.63) | SLC5A2SLC5A1CYP19A1CTNNB1WNT3A | |
| SCHEMBL14104531 | 0.73 | SLC5A1 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL7581216 | 0.73 | SLC5A1 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL6725644 | 0.73 | SLC5A1 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL30268946 | 0.73 | SLC5A1 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL13953727 | 0.72 | SLC5A1 (0.83) | SLC5A2SLC5A1 | |
| SCHEMBL12808039 | 0.71 | SLC5A1 (0.86) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381361-B1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND PPAR MODULATORS | ORTHO MCNEIL JANSSEN PHARM (US) | 2009-02-25 | — | — | EP | disclosed |